Clinical Trials Browser

PIK3CA-Mutated Cancers

Colorectal Neoplasms

Breast Neoplasms

Breast Neoplasms

Neoplasm Metastasis

Breast Neoplasms

Solid Tumors

Breast Neoplasms

Metastatic Castration-Resistant Prostate Cancer

Breast Neoplasms

Breast Neoplasms

Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms

Endometrial Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Ovarian Neoplasms

Breast Neoplasms, Neoplasm, Residual

Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

Colorectal Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

Neoplasm Metastasis

Advanced Unresectable or Metastatic Solid Malignancy

Clinical Trials

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

UmbrellaMAX

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

optINAVO

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

INAVO121

InavoPC

INAVO123

INAVO122

MITO END-4

EndoMAP

INAVO120

Morpheus-panBC

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

BOUQUET

MiRaDoR

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

INAVO-CRC

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC

PERSEVERE

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

GeparPiPPa

CRAFT: The NCT-PMO-1602 Phase II Trial

MyTACTIC